Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 31, 2019
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG<i>MS</i>
Kumaran Deiva, Peter Huppke, Brenda Banwell, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
November 19, 2004
Stimulus and potassium-induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis
Siegrun Gabriel, Marleisje Njunting, Joern K Pomper, et al.
The Lancet. Neurology
|
July 14, 2018
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
Richard Hughes, Marinos C Dalakas, Ingemar Merkies, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 17, 2021
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study
Jun-Ichi Kira, Jin Nakahara, Denis V Sazonov, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 16, 2013
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
Fabrizio Stocchi, Olivier Rascol, Alain Destee, et al.
Therapeutic Advances in Neurological Disorders
|
March 25, 2024
Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons
Nicholas Riley, Christopher Drudge, Morag Nelson, et al.
Acta Neuropathologica
|
January 16, 2007
A new clinico-pathological classification system for mesial temporal sclerosis
Ingmar Blümcke, Elisabeth Pauli, Hans Clusmann, et al.
Neurology and Therapy
|
July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Stephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Acta Neuropathologica
|
March 12, 2009
Towards a clinico-pathological classification of granule cell dispersion in human mesial temporal lobe epilepsies
Ingmar Blümcke, Iris Kistner, Hans Clusmann, et al.
Frontiers in Immunology
|
April 18, 2022
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
Tjalf Ziemssen, Douglas L Arnold, Enrique Alvarez, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 31, 2019
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG<i>MS</i>
Kumaran Deiva, Peter Huppke, Brenda Banwell, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
November 19, 2004
Stimulus and potassium-induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis
Siegrun Gabriel, Marleisje Njunting, Joern K Pomper, et al.
The Lancet. Neurology
|
July 14, 2018
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
Richard Hughes, Marinos C Dalakas, Ingemar Merkies, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 17, 2021
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study
Jun-Ichi Kira, Jin Nakahara, Denis V Sazonov, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 16, 2013
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
Fabrizio Stocchi, Olivier Rascol, Alain Destee, et al.
Therapeutic Advances in Neurological Disorders
|
March 25, 2024
Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons
Nicholas Riley, Christopher Drudge, Morag Nelson, et al.
Acta Neuropathologica
|
January 16, 2007
A new clinico-pathological classification system for mesial temporal sclerosis
Ingmar Blümcke, Elisabeth Pauli, Hans Clusmann, et al.
Neurology and Therapy
|
July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Stephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Acta Neuropathologica
|
March 12, 2009
Towards a clinico-pathological classification of granule cell dispersion in human mesial temporal lobe epilepsies
Ingmar Blümcke, Iris Kistner, Hans Clusmann, et al.
Frontiers in Immunology
|
April 18, 2022
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
Tjalf Ziemssen, Douglas L Arnold, Enrique Alvarez, et al.
Page
of 3